Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis.

Vujčić M, Sanja M, Jasminka JP, Marija P, Davor G, Ena R, Ana B

Open source

DOI
10.1016/j.jtha.2026.08.009
Published
2026 Aug 19
Container
Journal of thrombosis and haemostasis : JTH
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtha.2026.08.009,
  title = {Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis.},
  author = {Vujčić M and Sanja M and Jasminka JP and Marija P and Davor G and Ena R and Ana B},
  year = {2026},
  journal = {Journal of thrombosis and haemostasis : JTH},
  doi = {10.1016/j.jtha.2026.08.009},
  url = {https://doi.org/10.1016/j.jtha.2026.08.009}
}

RIS

TY  - JOUR
TI  - Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis.
AU  - Vujčić M
AU  - Sanja M
AU  - Jasminka JP
AU  - Marija P
AU  - Davor G
AU  - Ena R
AU  - Ana B
PY  - 2026
JO  - Journal of thrombosis and haemostasis : JTH
DO  - 10.1016/j.jtha.2026.08.009
UR  - https://doi.org/10.1016/j.jtha.2026.08.009
ER  - 

APA

M, V., M, S., JP, J., P, M., G, D., R, E., & B, A. (2026). Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis.. Journal of thrombosis and haemostasis : JTH. https://doi.org/10.1016/j.jtha.2026.08.009

Source records